28. USEFULNESS OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) AS A PREDICTOR FOR LEFT VENTRICULAR HYPERTROPHY (LVH) IN PATIENTS WITH HYPERTENSION: A SYSTEMATIC REVIEW AND META-ANALYSES. (May 2021)

• Record Type: Journal Article
• Authors: Multazam, Rachmatu Bill; Nawing, Aqila Ghaezany; Kamarullah, William; Josephine, Claudia Mary; Nurcahyani,
• Is Part Of: Journal of hypertension. Volume 39(2021)e-Supplement 2
• Publication Date: 2021-05
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000752460.12125.91
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Background: Left ventricular hypertrophy (LVH) is a common pathological change in hypertension, which is a marker for cardiovascular events and mortality. Inflammation as well as ischemia play significant roles and are the leading pathways in left ventricular remodeling. Thus, neutrophil-to-lymphocyte ratio (NLR), an inflammatory marker, was suggested to be predictive of LVH in hypertensive patients. Objective: Our aim was to review all studies that assessed the value of NLR in predicting LVH in hypertension. Methods: We performed a systematic literature search on the topic from several electronic databases (PubMed, Europe PMC, ProQuest, EBSCOhost, and Google Scholar) from inception to January 2021. The standardized mean difference (SMD) with 95% confidence interval (CI) were estimated and pooled to investigate the effect sizes. Results: Meta-analysis of two studies showed that increase in NLR was associated with higher risk of developing LVH in patients with hypertension (SMD = 0.68, 95% confidence interval [CI] = 0.12–1.25, Z = 2.36, P = 0.02) compared with control group. Additionally, further subgroup analyses of LVH categorization stratified by Ganau's classification showed significant higher NLR value in eccentric LVH subgroup (SMD = 1.22, 95% CI = 0.08–2.36, Z = 2.11, P = 0.04) although no significant difference was observed in other three subgroups. Conclusion: In this current meta-analysis, we concluded that NLR is a reliable and inexpensive biomarker to help determine risk of developing LVH in patients with hypertension.